Samsung Bioepis Obtains First Drug Approval in the United States as the U.S. Food and Drug Administration Approves RENFLEXIS Infliximababda Across All Eligible Indications

Monday April 24th 2017 at 506am UTC INCHEON Korea&8211;BUSINESS WIRE&8211; Samsung Bioepis Co. Ltd. today announced that the U.S. Food and Drug Administration FDA has approved RENFLEXIS infliximababda a biosimilar referencing RemicadeÂi infliximab ...